New Brazilian Pharmacopeia publications come into force.

On July 1st, four new publications of the Brazilian Pharmacopeia came into effect. Approved by the Brazilian Health Regulatory Agency (Anvisa) in May, these editions were launched at the 16th International Meeting of World Pharmacopeias, held from June 15 to 18 (2026) in Brasília-Brazil.

The event was important to mark the centenary of the Brazilian Pharmacopeia (1926–2026) and concluded the five-year term of the Brazilian Pharmacopeia’s collegiate bodies (2021–2026).

The new compendia:

- Brazilian Pharmacopeia, 8th edition

- Homeopathic Pharmacopeia, 4th edition

- Brazilian Pharmacopeia Formulary, 3rd edition

- Brazilian Pharmacopeia Herbal Medicines Formulary, 3rd edition

Check out some highlights of the above-mentioned publications:

Brazilian Pharmacopeia, 8th edition

•             19 new texts added

•             122 texts revised

•             203 errata incorporated

Homeopathic Pharmacopeia, 4th edition

•             nine new monographs were included

•             macroscopic and microscopic images into eight existing monographs were incorporated

•             21 new texts included

•             37 items in this compendium revised

Brazilian Pharmacopeia Formulary, 3rd edition

•             eight new texts included

•             four texts revised

Brazilian Pharmacopeia Herbal Medicines Formulary, 3rd edition

•             updates made during the five-year work cycle were consolidated

•             definitions with the new regulatory framework were harmonized

•             a coding system for all monographs was implemented

For further technical information regarding the new compendia, it is recommended to consult the documents available on the Public Consultations webpages on Public Consultations > Pharmacopoeia macro-topic.

Reference

The Brazilian Pharmacopeia is the national pharmaceutical compendium that establishes—through pharmacopeial texts (chapters, methods, and monographs)—the minimum requirements for quality, authenticity, and purity regarding pharmaceutical inputs, medicines, and other products under health surveillance. In other words, it should be used as a scientific reference to confirm the quality of drugs and raw materials. It is also a valuable source of regulatory information.